Intrapartum Glycemic Control in GDMA2

Last updated: June 3, 2024
Sponsor: Inova Health Care Services
Overall Status: Terminated

Phase

N/A

Condition

Diabetes (Pediatric)

Hormone Deficiencies

Pregnancy

Treatment

Blood sugar check every 4 hours

Blood sugar check every 2 hours

Clinical Study ID

NCT05647798
U22-01-4642
Protocol #20222678 U22-01-4642
  • Ages > 18
  • Female
  • Accepts Healthy Volunteers

Study Summary

This is a randomized, parallel, controlled, non-inferiority trial to assess the impact of a tight versus a more liberalized intrapartum glycemic control in gestational diabetic mothers on neonatal glycemia. National guidelines for the management of intrapartum glucose in women with GDM are lacking. This is likely due to the scarcity of high-quality data on the topic.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women 18 years or older

  • Non-anomalous singleton gestation

  • Gestational diabetes type A2 diagnosed at 24 weeks' gestation or beyond

  • Planned vaginal delivery at term at Inova Fairfax Women's Hospital

Exclusion

Exclusion Criteria:

  • Women < 18 years

  • Fetus with major congenital malformations

  • Twin or higher order gestation

  • Pre-existing diabetes mellitus

  • Exposure to antenatal or any systemic steroids 14 days or less prior to delivery

  • Preterm delivery

  • Scheduled cesarean birth

  • Intrapartum cesarean birth prior to 4-5 cm of cervical dilatation

Study Design

Total Participants: 2
Treatment Group(s): 2
Primary Treatment: Blood sugar check every 4 hours
Phase:
Study Start date:
May 22, 2023
Estimated Completion Date:
May 15, 2024

Study Description

Gestational diabetes mellitus (GDM) remains a common pregnancy complication, affecting 6-15% of pregnancies worldwide. The incidence of GDM is expected to continue its global upward trend in light of the growing obesity epidemic and delayed childbearing. GDM is associated with adverse short- and long-term maternal and offspring outcomes. Neonatal hypoglycemia, as a result of fetal hyperinsulinemia, occurs in up to 35% of pregnancies complicated by GDM with potential long-term neurodevelopmental sequelae. In that regard, significant emphasis has been placed on the prevention of neonatal hypoglycemia through optimal maternal glycemic control. Available data are conflicting as to the contribution of intrapartum glycemia to neonatal glycemia.

Moreover, national guidelines for the management of intrapartum glucose in women with GDM are lacking. This is likely due to a lack of high-quality data on the topic. As far as we are aware, only one single center randomized controlled trial has been published on the topic. That study's findings suggest that an approach to a more liberalized intrapartum glycemic management was not associated with a higher rate of neonatal hypoglycemia compared to a tight glycemic control regimen. We propose to replicate these findings in a different population at our institution. If this more relaxed approach to intrapartum glycemic management is confirmed to be safe to women and their babies, its clinical application has the potential to decrease the inconvenience of frequent finger pricks for our patients during labor and allow more efficient allocation of resources for the nursing staff on an already labor-intensive unit.

Connect with a study center

  • Inova Fairfax Medical campus

    Falls Church, Virginia 22042
    United States

    Site Not Available

  • Inova Health Care Services

    Falls Church, Virginia 22042
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.